Key Takeaways Grayscale says Bitcoin’s recent drop looks like a mid-bull-market correction, not a collapse. The firm argues that the […] The post Bitcoin Isn’t Crashing – Here’s What Grayscale Thinks Is Really Happening appeared first on Coindoo.Key Takeaways Grayscale says Bitcoin’s recent drop looks like a mid-bull-market correction, not a collapse. The firm argues that the […] The post Bitcoin Isn’t Crashing – Here’s What Grayscale Thinks Is Really Happening appeared first on Coindoo.

Bitcoin Isn’t Crashing – Here’s What Grayscale Thinks Is Really Happening

2025/12/02 23:00
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Key Takeaways

  • Grayscale says Bitcoin’s recent drop looks like a mid-bull-market correction, not a collapse.
  • The firm argues that the halving cycle has weakened because institutions now dominate demand.
  • Analysts see 2026 — not 2025 — as the probable window for new all-time highs. 

Among them is Grayscale, which argues that traders are misinterpreting the recent selloff — and that what looks like exhaustion may actually be the middle phase of an uptrend rather than the beginning of a collapse.

In other words: the downturn might be telling the opposite story of what most investors assume.

Bitcoin Didn’t “Break” — Traders Just Forgot How Bull Markets Behave

Grayscale’s research notes that Bitcoin has fallen 32% since October, briefly dipping to $84,000 before stabilizing around $86,900. The instinctive reaction has been fear that the cycle is over.

But Grayscale stresses that pullbacks of 25% or more are routine in major bull markets — not the signal that a peak has already happened. The firm says Bitcoin is still showing structural strength despite volatility rather than because of it.

Their position: volatility right now is a feature of the cycle, not proof that the cycle is ending.

The Old “Four-Year Clock” Doesn’t Explain This Market Anymore

For more than a decade, Bitcoin’s history seemed to revolve around halving events: supply shock → dramatic rally → harsh crash → reset.
This cycle is behaving differently.

READ MORE:

Vanguard Opens the Door to Crypto ETFs for 50 Million Investors

Grayscale says there’s a reason: the investor base has changed. Instead of retail speculation driving every phase of the market, institutional buyers now anchor the demand side — through ETFs, corporate treasury strategies and long-term allocation models.

That change means Bitcoin is reacting more to liquidity, interest rates and regulation than to a predictable four-year countdown.

What Could Push Bitcoin to New Highs

If the four-year cycle can no longer predict peaks, what can?
Grayscale flags three forces that didn’t exist in previous eras and now carry outsized influence:

• institutional allocations through ETFs
• expected rate cuts that would ease liquidity conditions
• rare bipartisan momentum for U.S. crypto legislation

Together, the firm suggests, those factors could set the stage for Bitcoin to explore new price territory in 2026 — with or without a halving-driven mania.

Others Are Reaching the Same Conclusion

BitMine CEO Tom Lee — known for his Ethereum-first perspective — lands on the same timeline, projecting that Bitcoin could set a new record as early as January 2026 if macro conditions tilt supportive.

The unexpected overlap between analysts who normally disagree has given weight to the idea that the recent selloff didn’t mark the top — it marked an interruption.


The information provided in this article is for educational purposes only and does not constitute financial, investment, or trading advice. Coindoo.com does not endorse or recommend any specific investment strategy or cryptocurrency. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

The post Bitcoin Isn’t Crashing – Here’s What Grayscale Thinks Is Really Happening appeared first on Coindoo.

Market Opportunity
Threshold Logo
Threshold Price(T)
$0.006506
$0.006506$0.006506
-1.22%
USD
Threshold (T) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09